Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback